Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01404806 · ClinicalTrials.gov registry record · Phase 1
GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01404806 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 10 participants.
The verdict
NCT01404806, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to describe drug concentrations of an investigational HIV medication, GSK1349572, in blood plasma, cervicovaginal fluid, vaginal and cervical tissue in HIV negative women.
Interventions
- DRUG GSK1349572 (dolutegravir)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01404806
The ClinicalTrials.gov registry entry for NCT01404806 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK1349572 (dolutegravir) is the first listed.
NCT01404806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01404806 about?
NCT01404806 is a clinical study titled "GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects". The purpose of this study is to describe drug concentrations of an investigational HIV medication, GSK1349572, in blood plasma, cervicovaginal fluid, vaginal and cervical tissue in HIV negative women.
What is the current status of trial NCT01404806?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-08. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01404806?
The interventions under investigation include: GSK1349572 (dolutegravir) (DRUG).
Who is sponsoring clinical trial NCT01404806?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.